| Target Price | $45.90 |
| Price | $38.60 |
| Potential |
18.91%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Royalty Pharma plc - Ordinary Shares - Class A 2026 .
The average Royalty Pharma plc - Ordinary Shares - Class A target price is $45.90.
This is
18.91%
register free of charge
$58.80
52.33%
register free of charge
$35.02
9.28%
register free of charge
|
|
| A rating was issued by 15 analysts: 12 Analysts recommend Royalty Pharma plc - Ordinary Shares - Class A to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Royalty Pharma plc - Ordinary Shares - Class A stock has an average upside potential 2026 of
18.91%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 2.26 | 3.10 |
| 3.86% | 37.13% | |
| EBITDA Margin | 57.10% | 94.75% |
| 9.90% | 65.95% | |
| Net Margin | 37.95% | 89.75% |
| 21.27% | 136.51% |
12 Analysts have issued a sales forecast Royalty Pharma plc - Ordinary Shares - Class A 2025 . The average Royalty Pharma plc - Ordinary Shares - Class A sales estimate is
This results in the following potential growth metrics:
12 Royalty Pharma plc - Ordinary Shares - Class A Analysts have issued a net profit forecast 2025. The average Royalty Pharma plc - Ordinary Shares - Class A net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.44 | 4.81 |
| 23.40% | 234.03% | |
| P/E | 8.02 | |
| EV/Sales | 9.48 |
12 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast for earnings per share. The average Royalty Pharma plc - Ordinary Shares - Class A EPS is
This results in the following potential growth metrics and future valuations:
Royalty Pharma plc - Ordinary Shares - Class A...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| TD Cowen |
Locked
➜
Locked
|
Locked | Dec 11 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Oct 10 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Sep 30 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Jul 22 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Jul 10 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Oct 25 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
TD Cowen:
Locked
➜
Locked
|
Dec 11 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Oct 10 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Sep 30 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Jul 22 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Jul 10 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Oct 25 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


